Skip to content Skip to content

Press Releases


Filter Releases
 
INCLINE VILLAGE, Nev., March 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2016 including: Total revenues of $66.5 million and $244.3 million for the three and twelve months ended December 31, 2016, respectively. GAAP...
INCLINE VILLAGE, Nev., March 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that the company's board of directors has authorized the repurchase of up to $30 million of the company's common stock through March 2018.  Purchases may be made in open-market transactions, block transactions on or off an exchange, in priv...
INCLINE VILLAGE, Nev., Feb. 22, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2016 financial results for the period ended December 31, 2016, on Wednesday, March 1, 2017, after market close. PDL's management will host a conference call and webca...
INCLINE VILLAGE, Nev., Feb. 17, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will participate in a fireside chat at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York. The session will be webcast live and will occur on...
INCLINE VILLAGE, Nev., Nov. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes due December 1, 2021 (2021 Notes).  PDL issued $150.0 million aggregate principal amount of 2021 Notes.  In addition, PDL has granted the underwriters an...
INCLINE VILLAGE, Nev., Nov. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 28th Annual Piper Jaffray Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, Novemb...
INCLINE VILLAGE, Nev., Nov. 17, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has agreed to sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the Notes) in an underwritten public offering.  The conversion rate of the Notes will initially be 262.2951 shares of commo...
INCLINE VILLAGE, Nev., Nov. 15, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1, 2021 (the Notes) under PDL's shelf registration statement filed with the U.S. Securiti...
INCLINE VILLAGE, Nev., Nov. 3, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2016 including: Total revenues of $53.6 million and $177.8 million for the three and nine months ended September 30, 2016, respectively. GAAP diluted EP...
INCLINE VILLAGE, Nev., Oct. 27, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2016 financial results for the period ended September 30, 2016, on Thursday, November 3, 2016, after market close. PDL's management will host a conference call and webcast that ...
INCLINE VILLAGE, Nev., Aug. 29, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that PDL has received approximately $57.4 million in connection with the termination of PDL's credit agreement with Paradigm Spine, LLC, which included a repayment of the full principal amount outstanding of $54.7 million as ...
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2016 including: Total revenues of $21.0 million and $124.2 million for the three and six months ended June 30, 2016, respectively. GAAP diluted EPS of $0.03...
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that its board of directors has decided to eliminate its quarterly cash dividend. John P. McLaughlin, president and chief executive officer of PDL, stated, "Since 2009, our dividends have been an important element of ou...
INCLINE VILLAGE, Nev., Aug. 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreeme...
INCLINE VILLAGE, Nev., July 28, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at...
= add release to Briefcase